Who Qualifies for Lawsuits for Depo-Provera and Meningiomas

Depo-Provera Lawsuits: Who May Be Eligible to Seek Justice for Meningioma Brain Tumors

Women across the United States are now stepping forward with Depo-Provera lawsuits, alleging that long-term use of this contraceptive shot caused them to develop meningiomas-serious, sometimes life-altering brain tumors. As more research emerges, many are asking if they or their loved ones qualify to take legal action against Pfizer, the manufacturer of Depo-Provera.

Depo-Provera, an injectable contraceptive containing medroxyprogesterone acetate, has been on the market since 1992. But disturbing evidence suggests a significant association between extended use of the drug and the development of meningiomas, which are tumors arising from the protective membranes covering the brain and spinal cord. Although often non-cancerous, these tumors can still cause devastating symptoms like seizures, vision problems, memory loss, and, in some cases, permanent neurological damage.

As of 2025, numerous lawsuits have been filed, many now consolidated into multidistrict litigation (MDL No. 3140) in the Northern District of Florida under Judge M. Casey Rodgers. Plaintiffs allege that Pfizer failed to warn about these risks despite knowing for decades that the hormone in Depo-Provera could contribute to abnormal brain cell growth by binding to progesterone receptors in the brain’s meninges.

The Scientific Link Between Depo-Provera and Meningiomas

At the heart of the Depo-Provera meningioma risk lawsuits lies compelling scientific evidence. Studies dating back to the 1980s revealed that meningiomas often contain high concentrations of progesterone receptors. Since medroxyprogesterone acetate-the active ingredient in Depo-Provera-mimics progesterone, it can stimulate these receptors, potentially triggering abnormal growth of meningeal cells and tumor formation.

In March 2024, a landmark study published in The British Medical Journal confirmed that women who used Depo-Provera for more than one year faced a 5.6-fold increased risk of developing intracranial meningiomas compared to non-users. This risk appears to grow with longer use and higher cumulative doses.

Adding to the concern, many of these tumors develop in particularly sensitive areas of the brain, like the skull base, making them extremely difficult to treat. Surgery may be risky or even impossible. As one patient described, “You’re just waiting for the next seizure or symptom to hit, living in constant uncertainty.”

International regulatory bodies in Canada, the European Union, and Australia have responded by adding explicit meningioma warnings to Depo-Provera labels. In contrast, the U.S. FDA has yet to require such warnings, prompting many of the current legal claims that Pfizer failed to provide American patients with adequate information.

Who May Qualify for Depo-Provera Lawsuits?

Determining eligibility for Depo-Provera lawsuits involves a careful review of several factors. Based on the current litigation and medical evidence, the following criteria generally apply:

• Depo-Provera Use History: The individual received at least two Depo-Provera injections after 1992, when it was FDA-approved for contraceptive use in the U.S.
• Diagnosis of Meningioma: The patient was diagnosed with a meningioma at least three years after starting Depo-Provera injections. This delay helps establish a temporal link between usage and tumor development.
• Age Factor: Most claims involve women diagnosed under the age of 70. The older the patient, the harder it may be to prove the tumor resulted from Depo-Provera rather than natural aging or unrelated factors.

Other eligibility considerations may include the size and location of the tumor, the severity of medical complications, and whether surgery or radiation was required. For example, patients with large tumors pressing against critical brain regions-causing vision loss, memory decline, or seizures-may have stronger legal claims and potentially higher compensation.

In some emerging cases, claims are also being filed for related conditions such as pseudotumor cerebri (idiopathic intracranial hypertension), where patients experience elevated brain pressure without an actual tumor present. This could lead to additional litigation avenues in the future.

Our attorneys are already working closely with many women and families facing these circumstances. If you believe you may qualify for a Depo-Provera lawsuit, contact Alonso Krangle, LLP today or use our confidential online form to start your free case review.

The Legal Claims Against Pfizer in Depo-Provera Litigation

Central to the Pfizer Depo-Provera litigation are serious allegations that the company knew or should have known about the drug’s meningioma risk for decades but failed to properly warn doctors and patients in the United States. This failure to warn forms the backbone of most lawsuits now being filed.

Internal documents obtained through discovery suggest that Pfizer and its predecessor companies had access to scientific research as early as the 1980s connecting progesterone and meningioma growth. Studies repeatedly indicated that medroxyprogesterone acetate could bind to progesterone receptors in meningioma cells and promote abnormal growth. Still, Depo-Provera reached the U.S. market in 1992 without any warning about this risk.

Adding to the controversy, while Pfizer updated product labels in many international markets-including Canada, the EU, and Australia-the company did not include similar meningioma warnings in U.S. labeling. Plaintiffs argue this created a dangerous two-tiered system where women in other countries received critical safety information that American women were denied.

The lawsuits also allege defective design claims, pointing out that Depo-Provera delivers a high dose of medroxyprogesterone acetate (150 mg every three months), even though lower-dose or non-hormonal alternatives exist. Plaintiffs assert that Pfizer prioritized profits over patient safety by failing to redesign the drug or provide safer alternatives when risks became apparent.

The Growing Depo-Provera Class Action and MDL Consolidation

As more women come forward, Depo-Provera claims have expanded rapidly, leading to the formation of the Depo-Provera class action-though technically, most U.S. cases are consolidated into federal multidistrict litigation (MDL), rather than a traditional class action. MDL No. 3140 was created in early 2025 and is currently centralized in the Northern District of Florida under Judge M. Casey Rodgers, who is overseeing pretrial proceedings.

One major benefit of the MDL process is that plaintiffs from across the country can file directly into the MDL, bypassing lengthy state court processes. Discovery, expert witness depositions, and document production are being coordinated to prevent duplicative efforts. As of mid-2025, over 130 individual lawsuits have been consolidated into this proceeding, with projections estimating thousands more potential claims.

In addition to the MDL, some lawsuits are proceeding in state courts in California, Pennsylvania, Missouri, Indiana, and elsewhere. These state-level cases allow plaintiffs to seek relief under state consumer protection laws and may reach trial faster than federal bellwether cases, increasing the legal pressure on Pfizer to negotiate settlements.

Judge Rodgers has already set an aggressive discovery schedule, with Daubert hearings on expert scientific testimony expected in early 2026, followed by potential bellwether trials. The outcome of these trials will likely set the tone for broader settlement discussions affecting thousands of women nationwide.

The Injuries and Damages Being Pursued in Depo-Provera Lawsuits

The injuries claimed in these lawsuits are severe, often life-altering, and in some cases permanent. Many women who developed meningiomas after using Depo-Provera have required invasive brain surgery to remove tumors. Others live with tumors that are inoperable due to their location near vital structures in the brain, such as the optic nerve or brainstem.

Common injuries and complications cited in these cases include:

• Chronic headaches and migraines
• Partial or complete vision loss
• Seizures and neurological deficits
• Cognitive impairment and memory loss
• Psychological harm, including anxiety and depression
• Ongoing medical monitoring and repeated MRI scans

For many plaintiffs, these injuries lead to lost income, diminished earning capacity, and permanent disability. In some situations, family members have become full-time caregivers for loved ones suffering from these debilitating conditions. Beyond financial losses, these lawsuits seek compensation for pain, suffering, loss of enjoyment of life, and future medical expenses related to ongoing tumor monitoring or additional surgeries.

Our attorneys are helping clients document their injuries fully and pursue the maximum possible recovery in their cases. If you have experienced these symptoms after using Depo-Provera, contact Alonso Krangle, LLP or submit your information through our secure to start your free case evaluation today.

Challenges Plaintiffs Face When Filing Depo-Provera Lawsuits

While the scientific evidence linking Depo-Provera to meningiomas is compelling, plaintiffs still face significant hurdles when pursuing Depo-Provera lawsuits. One of the most challenging aspects of these cases is proving causation. Defense attorneys for Pfizer argue that meningiomas are generally slow-growing and may have developed for reasons unrelated to Depo-Provera use, such as genetic predispositions or hormonal fluctuations unrelated to contraception.

Another obstacle involves medical documentation. Plaintiffs must establish a clear timeline of Depo-Provera use and show that their tumor developed after prolonged exposure to the drug. Because many women used the medication years or even decades ago, obtaining old pharmacy, insurance, or military healthcare records can be difficult. Courts have begun allowing subpoenas to access these records from third parties, but this process remains complex and time-consuming.

Additionally, Pfizer has argued that federal law preempts state law claims because the FDA has not required meningioma warnings on the U.S. label. This preemption defense will likely become a key legal battle in upcoming court proceedings, as plaintiffs argue that Pfizer could have voluntarily requested label changes or provided updated safety information independent of FDA mandates.

Despite these challenges, the growing body of scientific research, combined with Pfizer’s alleged long-standing knowledge of the risk, continues to strengthen plaintiffs’ legal positions as the litigation moves forward.

What Compensation Could Be Available in Depo-Provera Cases?

While every case is unique, plaintiffs in the ongoing Depo-Provera meningioma risk litigation may be entitled to several categories of financial compensation depending on the specifics of their injuries:

• Medical Expenses: Costs for surgeries, hospitalizations, diagnostic scans (like MRIs), radiation, follow-up care, medications, and ongoing medical monitoring.
• Lost Wages: Compensation for time missed from work during treatment and recovery, as well as future loss of earning capacity for those unable to return to work.
• Pain and Suffering: Damages for the physical and emotional toll of living with a brain tumor or undergoing invasive surgeries.
• Permanent Disability: Financial support for long-term or permanent neurological damage that impacts daily functioning.
• Loss of Quality of Life: Compensation for diminished enjoyment of life activities due to chronic headaches, seizures, vision impairment, or cognitive decline.

In some cases, juries may also consider awarding punitive damages if it is proven that Pfizer acted with gross negligence or willful disregard for patient safety by withholding known risks from the public.

Settlement negotiations will likely be influenced by the results of the upcoming bellwether trials scheduled for 2026. Early resolution may be possible in certain cases depending on the severity of injuries and the strength of the available evidence.

Contact Us to Discuss Your Potential Depo-Provera Lawsuit

If you or a loved one developed a meningioma after using Depo-Provera, you may have a strong claim against Pfizer. The science supporting these cases continues to grow, and litigation is advancing rapidly. However, strict deadlines apply, and gathering the right medical and legal documentation takes time.

Our lawyers at Alonso Krangle, LLP are actively representing women nationwide in these complex cases. We understand the devastating impact a brain tumor diagnosis can have on your health, your family, and your financial future. Let us review your medical history, investigate your Depo-Provera use, and guide you through your legal options at no cost to you.

Call us at [PHONE] or submit your details securely through our contact form. There is no fee unless we recover compensation for you. Do not wait-your time to file a claim may be limited.